Pharma News

Pharma Courses 
PAGE Admission 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals
    30 March 2022

    FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals

    The U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. The FDA previously authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series. This action will now make a second booster dose of these vaccines available to other populations at higher risk for severe disease, hospitalization and death.

  • 30 March 2022
    Alembic Pharmaceuticals acquires 100 percent Stake in Aleor Dermaceuticals

    Alembic Pharmaceuticals Limited has acquired the balance 40 percent stake in Aleor Dermaceuticals Limited from its JV Partner Orbicular Pharmaceutical Technologies Private Limited to strengthen its skin-related manufacturing and marketing footprint. Aleor has product offerings across Cream, Gel, Ointment, Shampoo, Lotion, Solutions, Sprays, Foams, Microsponge and Nanoparticulate platform-based products.

  • 28 March 2022
    WHO establishes the Global Centre for Traditional Medicine in India

    The World Health Organization (WHO) and the Government of India today signed an agreement to establish the WHO Global Centre for Traditional Medicine. This global knowledge centre for traditional medicine, supported by an investment of USD 250 million from the Government of India, aims to harness the potential of traditional medicine from across the world through modern science and technology to improve the health of people and the planet.

  • 28 March 2022
    Aspirin May Reduce Death In Hospitalized COVID-19 Patients

    Researchers at the George Washington University published findings from the world’s largest cohort study showing that hospitalized patients with moderate COVID-19 who were given aspirin early on in their treatment had a lower risk of dying compared to patients who were not given aspirin.

  • 28 March 2022
    New pathway for DNA transfer discovered in tumor microenvironment

    University of Notre Dame researchers have discovered another way tumor cells transfer genetic material to other cells in their microenvironment, causing cancer to spread.

  • 28 March 2022
    New study reveals why HIV remains in human tissue even after antiretroviral therapy

    Thanks to antiretroviral therapy, HIV infection is no longer the life sentence it once was. But despite the effectiveness of drugs to manage and treat the virus, it can never be fully eliminated from the human body, lingering in some cells deep in different human tissues where it goes unnoticed by the immune system.

    Now, new research by University of Alberta immunologist Shokrollah Elahi reveals a possible answer to the mystery of why infected people can’t get rid of HIV altogether.

  • 28 March 2022
    Xenpozyme approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency

    The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for Xenpozyme  (olipudase alfa) for the treatment of adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD), a rare, progressive, and potentially life-threatening genetic disease.

  • 24 March 2022
    Pfizer recalls blood pressure medicines in US due to cancer causing impurities

    Pharma Giant Pfizer recalls blood pressure medicines, brand name as Accuretic from the US market over presence of cancer causing impurities. Accuretic is a combination of quinapril HCl and hydrochlorothiazide.

  • 24 March 2022
    Abbott got CDSCO panel nod to market Lidocaine and Diltiazem combination

    Abbott received permission from the Subject Expert Committee to market a fixed dose combination (FDC) of Lidocaine and Diltiazem, after detailed deliberation by committee.

    Abbott has presented a Phase III clinical trial report before the committee and after detailed deliberation, the committee recommended grant of permission for manufacturing and marketing of the proposed FDC.

  • 24 March 2022
    Indoco Remedies receives USFDA nod for Lacosamide Tablets

    Indoco Remedies Ltd. announces final approval from the United States Food and Drug Administration (USFDA) for Lacosamide Tablets USP 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat Tablets of UCB, Inc.

    Lacosamide Tablets are indicated for the prevention and control of seizures. It is an anticonvulsant / antiepileptic drug.

Subscribe to Pharma News